GeNeuro SA Announces Extension of Definitive Debt-Restructuring Moratorium
Geneva, Switzerland, 26 September 2025 – 6:00 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court of First Instance has, in a September 25, 2025, judgment, granted GeNeuro SA an extension of its definitive debt-restructuring moratorium until January 27, […]